RTW Biotech Opportunities Ltd (LSE: RTWG), a London-listed investment fund focused on the biopharmaceutical and medical technology sectors, has disclosed a share buyback transaction conducted on 13 November 2026. The company repurchased 329,580 ordinary shares at a price of $2.45 per share, with the repurchased shares to be held in treasury. The buyback reduces the company's total voting rights to 317,793,648, a figure shareholders may use as the denominator for FCA Disclosure and Transparency Rules calculations.

Key Points

  • RTW Biotech Opportunities Ltd (LSE: RTWG) — London-listed biopharmaceutical and medtech-focused investment fund managed by RTW Investments, LP
  • The company bought back 329,580 ordinary shares on 13 November 2026 at $2.45 per share, to be held in treasury
  • Total issued ordinary share capital stands at 345,967,440, with 28,173,792 shares now held in treasury carrying no voting rights; total voting rights are 317,793,648
  • Investors should monitor further buyback disclosures ahead of the next AGM, expected in 2027, when shareholder authority will be renewed

RTW Biotech's 13 November Buyback: Transaction Terms and Treasury Treatment

The announcement states that RTW Biotech Opportunities Ltd executed the repurchase of 329,580 ordinary shares at $2.45 per share on 13 November 2026. The repurchased shares will be held in treasury and will carry no voting rights, in line with standard UK company law treatment for treasury shares. The company has confirmed it is its current intention to retain bought-back shares in treasury rather than cancel them. No maximum total consideration for the overall buyback programme has been determined, and the company has stated it cannot pay a price that would equate to a premium to net asset value per share.

AGM-Granted Authority Permits Repurchase of Up to 14.99% of Ordinary Shares

The buyback is being conducted under authority granted to the board by shareholders at the company's Annual General Meeting in June 2026. That authority permits RTW Biotech to repurchase a maximum of 14.99% of its ordinary shares. The authority remains in force until it is superseded by a new shareholder resolution — expected at the 2027 AGM — or until expressly revoked. The announcement notes that the actual number of shares repurchased will depend on prevailing market conditions. Jefferies International Limited has been appointed as broker to manage the buyback transactions, an arrangement the company states is consistent with FCA Listing Rules.

Voting Rights Denominator Updated to 317,793,648 for FCA Disclosure Calculations

Following settlement of this transaction, RTW Biotech's total issued ordinary share capital stands at 345,967,440 shares, of which 28,173,792 are now held in treasury. Because treasury shares carry no voting rights, the company's total voting rights figure is 317,793,648. The announcement specifies that this figure should be used by shareholders as the denominator when determining whether they are required to notify an interest, or a change in interest, under the FCA's Disclosure and Transparency Rules — a regulatory obligation relevant to institutional and significant individual shareholders.

RTW Biotech's Investment Focus: Biopharmaceutical and Medical Technology Growth Assets

RTW Biotech Opportunities Ltd is an investment fund focused on identifying high-growth assets across the biopharmaceutical and medical technology sectors. The fund is managed by RTW Investments, LP, described in the announcement as a healthcare-focused entrepreneurial investment firm with scientific expertise and a track record of supporting companies developing life-changing therapies. The fund invests in businesses developing next-generation therapies and technologies with the aim of improving patient outcomes. Investors may watch how the ongoing buyback programme affects the fund's treasury position and voting structure as the 2027 AGM authority renewal approaches.